TrialThe Lancet. Oncology2021

Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial.

Dean A Fennell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.